Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cardiac Adverse Events With Remdesivir in COVID-19 Infection
Anupam Gupta, Barbara M Parker, Vikash Priyadarshi, et al.
Cureus (2020)
Open Access | Times Cited: 81

Showing 1-25 of 81 citing articles:

Cardiovascular complications of COVID-19
Farnaz Farshidfar, Navid Koleini, Hossein Ardehali
JCI Insight (2021) Vol. 6, Iss. 13
Open Access | Times Cited: 133
Impact of COVID-19 on Cardiovascular Disease
Ivan Vosko, Andreas Zirlik, Heiko Bugger
Viruses (2023) Vol. 15, Iss. 2, pp. 508-508
Open Access | Times Cited: 65
Potential Cardiotoxic Effects of Remdesivir on Cardiovascular System: A Literature Review
Maryam Nabati, Homa Parsaee
Cardiovascular Toxicology (2021) Vol. 22, Iss. 3, pp. 268-272
Open Access | Times Cited: 62
The Spectrum of Antibiotic Prescribing During COVID-19 Pandemic: A Systematic Literature Review
Sara H. Al-Hadidi, Hashim Alhussain, Hamad Abdel Hadi, et al.
Microbial Drug Resistance (2021) Vol. 27, Iss. 12, pp. 1705-1725
Open Access | Times Cited: 56
The efficacy and safety of remdesivir alone and in combination with other drugs for the treatment of COVID-19: a systematic review and meta-analysis
Chuizhe Chen, Junde Fang, Shu Chen, et al.
BMC Infectious Diseases (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 17
Sinus Bradycardia Associated with Remdesivir Treatment in COVID-19: A Case Report and Literature Review
Fotios Barkas, Chrysoula-Paraskevi Styla, Aris Bechlioulis, et al.
Journal of Cardiovascular Development and Disease (2021) Vol. 8, Iss. 2, pp. 18-18
Open Access | Times Cited: 37
COVID‐19 induced bradyarrhythmia and relative bradycardia: An overview
Steven Douedi, Anton Mararenko, Abbas Alshami, et al.
Journal of Arrhythmia (2021) Vol. 37, Iss. 4, pp. 888-892
Open Access | Times Cited: 37
Cardiac Events Potentially Associated to Remdesivir: An Analysis from the European Spontaneous Adverse Event Reporting System
Concetta Rafaniello, Carmen Ferrajolo, Maria Giuseppa Sullo, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 7, pp. 611-611
Open Access | Times Cited: 36
Identification of Bradycardia Following Remdesivir Administration Through the US Food and Drug Administration American College of Medical Toxicology COVID-19 Toxic Pharmacovigilance Project
Jason M. Devgun, Rongmei Zhang, Jeffrey Brent, et al.
JAMA Network Open (2023) Vol. 6, Iss. 2, pp. e2255815-e2255815
Open Access | Times Cited: 14
Cardiac Adverse Events and Remdesivir in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19): A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial
Vida Terzić, Joe Miantezila Basilua, Nicolas Billard, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 2, pp. 382-391
Open Access | Times Cited: 5
Effect of COVID‐19 medications on corrected QT interval and induction of torsade de pointes: Results of a multicenter national survey
Majid Haghjoo, Reza Golipra, Jalal Kheirkhah, et al.
International Journal of Clinical Practice (2021) Vol. 75, Iss. 7
Open Access | Times Cited: 31
Severe sinus bradycardia associated with Remdesivir in a child with severe SARS-CoV-2 infection
María Isabel Sánchez-Códez, Moisés Rodríguez‐González, Irene Gutiérrez-Rosa
European Journal of Pediatrics (2021) Vol. 180, Iss. 5, pp. 1627-1627
Open Access | Times Cited: 29
Bradycardia associated with remdesivir therapy for COVID-19 in a 59-year-old man
Leora Branfield Day, Husam Abdel‐Qadir, Michael Fralick
Canadian Medical Association Journal (2021) Vol. 193, Iss. 17, pp. E612-E615
Open Access | Times Cited: 29
Safety profile of COVID-19 drugs in a real clinical setting
Mei Nee Chiu, Maitry Bhardwaj, Sangeeta Pilkhwal Sah
European Journal of Clinical Pharmacology (2022) Vol. 78, Iss. 5, pp. 733-753
Open Access | Times Cited: 21
Multi-target potential of Indian phytochemicals against SARS-CoV-2: A docking, molecular dynamics and MM-GBSA approach extended to Omicron B.1.1.529.
Jency Roshni, R. Vaishali, KS Ganesh, et al.
Journal of Infection and Public Health (2022) Vol. 15, Iss. 6, pp. 662-669
Open Access | Times Cited: 20
Remdesivir might induce changes in electrocardiogram beyond bradycardia in patients with coronavirus disease 2019—The pilot study
Petra Bistrović, Marko Lucijanić
Journal of Medical Virology (2021) Vol. 93, Iss. 10, pp. 5724-5725
Open Access | Times Cited: 27
Adverse Cardiovascular Effects of Anti-COVID-19 Drugs
Dongling Liu, Xiang Zeng, Zufeng Ding, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 26
Safety and heart rate changes in Covid-19 patients treated with Remdesivir
Natale Daniele Brunetti, Mariacristina Poliseno, Irene Francesca Bottalico, et al.
International Journal of Infectious Diseases (2021) Vol. 112, pp. 254-257
Open Access | Times Cited: 24
Cryotherapy for treatment of sporotrichosis—rapid cure with adjuvant cryotherapy: case report
Prajwal Pudasaini, Sushil Paudel, G C Sagar, et al.
Journal of Medical Case Reports (2025) Vol. 19, Iss. 1
Open Access
Sinus Bradycardia in a Pediatric Patient Treated With Remdesivir for Acute Coronavirus Disease 2019: A Case Report and a Review of the Literature
Eric J. Chow, Branden Maust, Katherine M. Kazmier, et al.
Journal of the Pediatric Infectious Diseases Society (2021) Vol. 10, Iss. 9, pp. 926-929
Open Access | Times Cited: 21
Remdesivir-Induced Bradycardia
Sai Gautham Kanagala, Hardeep Dholiya, Poonam Jhajj, et al.
Southern Medical Journal (2023) Vol. 116, Iss. 3, pp. 317-320
Open Access | Times Cited: 9
Cardiovascular adverse effects of antiviral therapies for COVID-19: Evidence and plausible mechanisms
Eileen Chen, Lei Xi
Acta Pharmacologica Sinica (2024)
Open Access | Times Cited: 3
Remdesivir: Quo vadis?
Erik De Clercq
Biochemical Pharmacology (2021) Vol. 193, pp. 114800-114800
Open Access | Times Cited: 20
Applying polypharmacology approach for drug repurposing for SARS-CoV2
Esther Jamir, Himakshi Sarma, Lipsa Priyadarsinee, et al.
Journal of Chemical Sciences (2022) Vol. 134, Iss. 2
Open Access | Times Cited: 14
Pharmacology and Adverse Events of Emergency-Use Authorized Medication in Moderate to Severe COVID-19
Jen‐Yu Hsu, Yan–Chiao Mao, Po‐Yu Liu, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 10, pp. 955-955
Open Access | Times Cited: 18
Page 1 - Next Page

Scroll to top